POINT Biopharma Global Gross Profit

As of the most recent data (September 2023), PNT shows a gross profit of $9.7B. That is below the Healthcare sector average of $66B. Scroll down for historical charts and peer comparison views.

The Healthcare sector average gross profit is about $66B. POINT Biopharma Global is at $9.7B, which is lower that average. That is roughly 85.2% below the sector mean. Use the comparison chart on this page to see how PNT stacks up against individual peers as well.

Tracking PNT's gross profit over time shows whether POINT Biopharma Global is scaling, shrinking, or reshaping that part of the business. The current reading is $9.7B Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has POINT Biopharma Global's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $9.7B) with ownership activity and broader fundamentals.

The Healthcare average gross profit is about $66B, while PNT is at $9.7B. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.